# High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer

> **NCT01198548** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Stage IV Colon Cancer
- Stage IV Rectal Cancer

## Interventions

- **DRUG:** leucovorin calcium
- **BIOLOGICAL:** bevacizumab
- **DIETARY_SUPPLEMENT:** cholecalciferol
- **DRUG:** fluorouracil
- **DRUG:** oxaliplatin
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT01198548
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2012-04
- **Final completion:** 2012-06
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2014-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01198548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01198548, "High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01198548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*